FDA warned HealBerry that claiming compounded semaglutide has the 'same active ingredient as Ozempic and Wegovy' misbrands its drugs.
What happened
In August 2025, FDA reviewed HealBerry's website at https://healberry.com and observed that it offers various compounded drug products, including semaglutide. FDA found the website claim 'Same active ingredient as Ozempic and Wegovy.' Because compounded drugs are not FDA-approved, FDA says the claim is false or misleading and misbrands the products.
What FDA found
HealBerry's website claim that its compounded semaglutide has the 'same active ingredient as Ozempic and Wegovy' is false or misleading because compounded drugs are not FDA-approved.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The misbranded compounded semaglutide products were introduced or delivered for introduction into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving, delivering, or offering delivery of the misbranded drugs in interstate commerce is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days of receipt, FDA asks HealBerry to send the Office of Compounding Quality and Compliance a written response describing steps taken to address the violations, prevent recurrence, and include supporting documentation. If HealBerry cannot complete the actions in that time, it must state the reason for delay and when it will finish.
Who should pay attention
- telehealth companies marketing compounded semaglutide
- compounding pharmacies and their marketing partners
- clinicians and brands referring patients to compounded weight-loss drugs
This is a summary. Read the original letter on fda.gov.